Neuronal polarity is essential for the proper development, growth, and physiology of neurons. Within neurons, microtubules (MTs) and motor protein polarities are required for establishing and maintaining neuronal polarity. However, unanswered questions remain: 1. Why are some cytoplasmic molecules in axons but not dendrites? 2. How do MAPs become compartmentalized differently in each type of neurite? 3. Why does a neuron have a single axon but multiple dendrites?⁵

To help you, the researcher, to answer these questions (as well as many others regarding MT functions in the central nervous system!) for a number of years now we’ve been providing a reliable range of kits by Cytoskeleton Inc. Their highly useful reagents include the Signal-Seeker Enrichment kits for quantifying levels of endogenous PTMs such as acetylation, tyrosine phosphorylation, ubiquitination, and SUMOylation, as well as purified cytoskeletal proteins (e.g., actins, tubulins, kinesin and dynein motors) and functional assay kits to measure the activities of these same proteins.

In a recently published study, researchers sought to elucidate if 2 treatments modulated immune response or not, despite the available evidence being conflicting. The method that made the difference and allowed them to reach their conclusions, is based on 16 human cytokines using multiplex immunoassays with the Quansys technology.

In a previous post, I introduced the C-series multiplex profiling technology from Raybiotech, a smart way to multiplex your western blot while saving time and sample volume, and decreasing the cost of your experiment.

Indeed, one blot for multiple targets processed at once is a nice way to boost your protein profiling studies!

I just wanted to highlight in this post, that on top of the standard species models like human, mouse and rat, these C-series are also available for many other models. With 15 different species to select from, RayBiotech is leading the way for immunoassay kit species diversity.

Monoclonal antibodies (mAbs) are used as immunotherapeutics to treat cancer and other diseases, and either aim to induce target cell destruction or immune cell activation. After binding to their cognate antigens, mAbs engage Fc gamma receptor  (FcγR), localised on the surface of the Immune cells, and identified by many research groups as regulator of mAbs activity. To help researchers working on immunotherapeutic mAbs development, BPS Bioscience have developed a new CHO K1 cell line stably expressing full length human FcGR2B.